User
User

Position

Hospital Cruces Bilbao

HEALTH CARE ONCOLOGY WORKFLOW

Texto legal y de aviso. Warning. para completar loream ABRAXANE is a microtubule inhibitor indicated for the treatment of: • Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an a

=

#CC1506

id Cancerappy

I

CANCER BREAST

Tumor Type

10/25/2019

Report Date

A

Sample

other information

This report provides:

  • FDA Approved Drugs
  • Medical indications
  • Pharmacology toxicities
  • Drugs interactions
  • Ongoing clinical studies
  • European and American guidelines
  • Molecular Biomarkers for personalized medicine
  • Real World Data
  • Best workflow to reduce medical effort

FDA Approved Drugs

Tumor Clasification

Gene Mutations

Drugs acting on affected pathways

Investigational Drugs with Common Pathways

3 drug

combinations

  • Drug name n1 + n2 + n3 83% 83%
  • Drug name n1 + n2 + n3 75% 75%
  • Drug name n1 + n2 + n3 68% 68%

2 drug

combinations

  • Drug name n1 + n2 58% 58%
  • Drug name n1 + n2 57% 57%
  • Drug name n1 + n2 53% 53%

1 drug

Monotherapies

  • Drug name 33% 33%
  • Drug name 33% 33%
  • Drug name 15% 15%

Most recent Treatment

  • Drug name 1% 1%
i

FDA Approved Drugs for: BREAST CANCER

    • Drug Name
      More Information
      Clasification Advers Reaction in Clinical Trials

Your Title Goes Here

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.